1. Name and Address of Reporting Person
Akinsanya Karen
C/O SCHRODINGER, INC.,
1540 BROADWAY, 24TH FLOOR
NEW YORK 10036

2. Issuer Name and Ticker or Trading Symbol
Schrodinger, Inc. [ SDGR ]

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2021

4. If Amendment, Date of Original Filed (Month/Day/Year)
09/15/2021

5. Relationship of Reporting Person(s) to Issuer
Director
10% Owner

6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
Form filed by More than One Reporting Person

---

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>1. Title of Security (Instr. 3)</th>
<th>2. Transaction Date (Month/Day/Year)</th>
<th>3. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>4. Transaction Code (Instr. 8)</th>
<th>5. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>6. Price</th>
<th>7. No. of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>09/15/2021</td>
<td></td>
<td>M(1)</td>
<td>A</td>
<td>$4.34</td>
<td>1,394</td>
</tr>
<tr>
<td>Common Stock</td>
<td>09/15/2021</td>
<td></td>
<td>G(1)</td>
<td>D</td>
<td>$61.13</td>
<td>0</td>
</tr>
</tbody>
</table>

---

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>1. Title of Derivative Security (Instr. 3)</th>
<th>2. Conversion or Exercise Price of Derivative Security</th>
<th>3. Transaction Date (Month/Day/Year)</th>
<th>4. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>5. Number of Derivative Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>6. Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>7. No. of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>8. Price of Derivative Security (Instr. 5)</th>
<th>9. No. of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)</th>
<th>10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>11. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Option (right to buy)</td>
<td>$4.34</td>
<td>09/15/2021</td>
<td></td>
<td>M(1)</td>
<td>1,394</td>
<td>(2) 11/29/2028</td>
<td>$0.00</td>
<td>44,591</td>
<td>D</td>
<td></td>
</tr>
</tbody>
</table>

Explanations of Responses:
1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2021.
2. This option was granted on November 29, 2018. The shares underlying the option vested with respect to 25% of the shares on December 31, 2019 and the remainder are scheduled to vest in equal monthly installments through December 31, 2022.

Remarks:
EVP, Chief Biomedical Scientist, Head of Discovery R&D

/s/ Donald Shum, as attorney-in-fact for Karen Akinsanya
09/16/2021

/s/ Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.